Alembic Pharmaceuticals gets USFDA approval

For Paclitaxel Injection USP

Alembic Pharmaceuticals has received US Food & Drug Administration (USFDA) Final Approval for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials. This is the first product approval for oncology injection from its F-2 Facility (Oncology Injectable) which recently completed the first USFDA inspection.

Powered by Capital Market - Live News